Spark Therapeutics, Inc. - FORM S-1/A - EX-23.1 - January 20, 2015

Attached files

file filename
S-1/A - AMENDMENT NO. 1 TO FORM S-1 - Spark Therapeutics, Inc.d776249ds1a.htm
EX-1.1 - EX-1.1 - Spark Therapeutics, Inc.d776249dex11.htm
EX-5.1 - EX-5.1 - Spark Therapeutics, Inc.d776249dex51.htm
EX-10.6 - EX-10.6 - Spark Therapeutics, Inc.d776249dex106.htm
EX-10.24 - EX-10.24 - Spark Therapeutics, Inc.d776249dex1024.htm
EX-10.5 - EX-10.5 - Spark Therapeutics, Inc.d776249dex105.htm
EX-10.8 - EX-10.8 - Spark Therapeutics, Inc.d776249dex108.htm
EX-10.25 - EX-10.25 - Spark Therapeutics, Inc.d776249dex1025.htm
EX-10.9 - EX-10.9 - Spark Therapeutics, Inc.d776249dex109.htm
EX-4.1 - EX-4.1 - Spark Therapeutics, Inc.d776249dex41.htm
EX-10.23 - EX-10.23 - Spark Therapeutics, Inc.d776249dex1023.htm
EX-10.26 - EX-10.26 - Spark Therapeutics, Inc.d776249dex1026.htm
EX-10.7 - EX-10.7 - Spark Therapeutics, Inc.d776249dex107.htm
EX-10.15 - EX-10.15 - Spark Therapeutics, Inc.d776249dex1015.htm
EX-10.21 - EX-10.21 - Spark Therapeutics, Inc.d776249dex1021.htm
EX-3.1 - EX-3.1 - Spark Therapeutics, Inc.d776249dex31.htm
EX-24.2 - EX-24.2 - Spark Therapeutics, Inc.d776249dex242.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Spark Therapeutics, Inc.:

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

Philadelphia, Pennsylvania

January 20, 2015

Spark Therapeutics, Inc. Reports